Quarterly Result5 May 2026, 07:21 pm
Jenburkt Pharma: FY26 Revenue at ₹168.74 Cr; Dividend ₹220.70/Share
AI Summary
Jenburkt Pharmaceuticals Ltd's board approved the standalone audited financial statements for the year ended March 31, 2026. The company reported revenue from operations of ₹168.74 Cr and a profit after tax of ₹34.73 Cr. A dividend of ₹220.70 (207%) per equity share of ₹10 each was declared. The 41st Annual General Meeting is scheduled for September 4, 2026, via video conferencing. Shri Dilip H. Bhuta was re-appointed as the Whole Time Director and CFO for five years effective April 1, 2027.
Key Highlights
- FY26 revenue from operations reached ₹168.74 Cr, compared to ₹151.69 Cr in FY25.
- The board approved a dividend of ₹220.70 per share for FY26.
- Dilip H. Bhuta re-appointed as Whole Time Director and CFO for five years from April 1, 2027.
- The Annual General Meeting will be held on September 4, 2026, via video conferencing.
- Auditors presented an unmodified opinion on the standalone audited financial statements.
Price Impact
More from JENBURPH*